Yes, investors in ImmunityBio are claiming they were misled about the approval and efficacy of the company’s cancer drug ANKTIVA. The company’s chairman made sweeping claims during a direct-to-consumer podcast in January 2026 that the drug could treat “all cancers,” despite FDA approval limiting it to a single type of bladder cancer. When the FDA issued a warning letter on March 13, 2026, challenging the company’s promotional materials as “false or misleading,” ImmunityBio’s stock price collapsed by 21 percent, wiping out $2 billion in market capitalization and causing shareholders to lose $1.98 per share. The lawsuit centers on a fundamental disconnect between what company leadership publicly stated about ANKTIVA’s potential and what the FDA actually approved.
Investors are alleging that management concealed critical drug limitations while promoting the treatment as a broad-spectrum cancer solution. This case highlights a common pattern in biotech litigation: companies making exaggerated efficacy claims to inflate stock value before the regulatory reality catches up with the marketing narrative. Multiple law firms, including Levi & Korsinsky and Hagens Berman, are actively investigating the matter and seeking lead plaintiffs to represent the investor class. The lawsuit targets a critical period when insiders knew about the drug’s limited FDA approval but continued to make expansive public statements about its capabilities.
Table of Contents
- What Were ImmunityBio’s Misleading Claims About Its Cancer Drug?
- The FDA Warning Letter That Changed Everything
- The Immediate Market Impact and Financial Losses
- Understanding ANKTIVA’s Actual FDA-Approved Limitations
- How This Case Illustrates Securities Law Violations
- Who Can Join the Class Action and What Recovery Looks Like
- The Broader Pattern of Biotech Misleading Claims
- Conclusion
What Were ImmunityBio’s Misleading Claims About Its Cancer Drug?
The heart of the litigation involves three specific categories of false or misleading statements made by company leadership. On January 19, 2026, ImmunityBio’s chairman stated during a direct-to-consumer podcast that while ANKTIVA had been approved for bladder cancer, “it actually can treat all cancers.” This single statement contradicted the company’s own regulatory filings and the FDA-approved labeling of the drug. The chairman went further, also claiming that ANKTIVA was a “cancer vaccine” and could be administered subcutaneously—both claims directly contradicted by the FDA’s actual approval documentation. The FDA’s analysis of ImmunityBio’s promotional materials revealed a pattern of systematic misrepresentation. In its warning letter, the agency determined that the company’s communications created “a misleading impression that Anktiva…can cure and even prevent all cancer.” This wasn’t casual exaggeration but rather carefully crafted messaging designed to overstate the drug’s efficacy in ways that directly contradicted FDA-approved labeling.
The pharmaceutical company promoted a cancer vaccine narrative when the FDA had approved ANKTIVA only as a treatment for a specific subset of bladder cancer patients—not as a preventive vaccine and not across the broader cancer spectrum. For investors, these claims mattered enormously. Biotech investors make decisions based on management’s candid assessments of pipeline potential. A drug that works across multiple cancer types is worth substantially more than one limited to 4.2 percent of annual cancer diagnoses. The gap between the chairman’s public statements and regulatory reality created the conditions for significant securities fraud claims.
The FDA Warning Letter That Changed Everything
On March 13, 2026, the FDA issued a formal warning letter to ImmunityBio, marking a critical turning point in the company’s credibility. The warning wasn’t a suggestion or a gentle reminder—it was an official regulatory document stating that the company’s promotional communications violated federal law by making unsubstantiated disease claims. The FDA determined that ImmunityBio lacked adequate substantiation for its assertions about the drug’s efficacy and its applicability to cancers beyond bladder cancer. The timing of the FDA letter mattered significantly for the legal case. Shareholders who owned the stock between January 19, 2026 (when the misleading podcast statement was made) and March 13, 2026 (when the FDA issued its warning) would fall within the class period for the lawsuit.
These investors held shares based on the company’s misrepresentations, only to watch the stock plummet when regulatory reality was publicly disclosed. The FDA’s formal warning created what securities lawyers call a “corrective disclosure”—a moment when the market abruptly repriced the stock based on previously undisclosed information. One critical limitation to understand: FDA warning letters don’t immediately stop a company from selling an approved drug. ANKTIVA remained on the market even after the warning was issued. However, the warning severely damaged investor confidence because it established that company leadership had knowingly made false statements about the drug’s capabilities, raising questions about what other representations might be inaccurate.
The Immediate Market Impact and Financial Losses
The stock market’s reaction to the FDA warning was swift and severe. In the trading sessions immediately following the disclosure, ImmunityBio shares declined 21 percent in value. This wasn’t a gradual erosion but rather a sharp repricing that reflected investors’ sudden recognition that the company’s prior statements were unreliable. The per-share loss of $1.98 may seem modest in isolation, but when multiplied across millions of shares held by institutional investors, small-cap funds, and individual shareholders, the aggregate losses reached $2 billion in market capitalization. To put this in perspective, consider an investor who purchased 1,000 shares of ImmunityBio stock at what they believed was a reasonable valuation based on management’s claims about ANKTIVA’s potential.
If that investor bought at $30 per share (a realistic price for a biotech company with a supposedly game-changing cancer drug), they would have invested $30,000. After the 21 percent decline, that position would be worth approximately $23,700—a loss of $6,300 on a single position. For retirement accounts and investment portfolios that held significant stakes in ImmunityBio, these losses were material. The $2 billion market cap destruction reflects the magnitude of the misrepresentation. When the market learned that the drug was limited to a single cancer type affecting roughly 4.2 percent of new cancer diagnoses annually, rather than the broad-spectrum cancer treatment the chairman had claimed, the company’s valuation collapsed accordingly. This gap between claimed potential and actual approved use is precisely what securities law is designed to remedy.
Understanding ANKTIVA’s Actual FDA-Approved Limitations
To fully grasp the scope of ImmunityBio’s misleading statements, it’s essential to understand what the FDA actually approved. ANKTIVA received approval specifically for non-muscle-invasive bladder cancer (NMIBC), a condition that represents approximately 4.2 percent of new cancer cases diagnosed annually in the United States. This is not a minor subset—it’s a genuine unmet medical need affecting roughly 50,000 patients per year. However, it’s also dramatically narrower than the “all cancers” claim the chairman made. The FDA approval came with specific labeling requirements and restrictions on how the drug could be promoted and administered. ImmunityBio’s claims that ANKTIVA could be given subcutaneously (under the skin) contradicted the approved administration protocol.
The company’s characterization of the drug as a “cancer vaccine” misrepresented the mechanism of action and suggested preventive capability when the drug was actually an immunotherapy treatment for an existing condition. These weren’t minor semantic differences—they represented material misstatements about the drug’s fundamental properties. A critical limitation that affected investor value was this: even for bladder cancer, the drug’s efficacy came with real-world constraints that weren’t adequately disclosed. Not all bladder cancer patients would benefit from ANKTIVA, and market penetration would be limited by patient eligibility criteria, physician adoption rates, and competing treatments. The chairman’s suggestion that the drug could “treat all cancers” inflated expectations far beyond what even the most optimistic realistic projections would support. For an investor evaluating the drug’s commercial potential, this distinction between approved use and claimed use created a massive valuation error.
How This Case Illustrates Securities Law Violations
The ImmunityBio litigation centers on three distinct legal theories: failure to disclose material information, affirmative misrepresentation, and breach of fiduciary duty. Securities law requires that company insiders—particularly executives and board members—disclose all material facts that would influence investor decisions. A material fact is one that would significantly alter a reasonable investor’s decision to buy, sell, or hold the security. The gap between ANKTIVA’s actual approved use and the chairman’s public claims about its potential clearly meets this threshold. The affirmative misrepresentation claim is straightforward: the chairman made false statements during a public podcast (a vehicle designed to reach investors and media), and those statements directly contradicted FDA-approved labeling.
Securities law doesn’t require proof that the company intended to defraud—only that material misstatements were made and investors relied on them to their detriment. In this case, the podcast appearance was clearly designed to influence public perception of the drug’s potential, and the statements were demonstrably false based on the FDA record. A practical limitation to recognize: not all shareholders who lost money will be eligible to participate in the class action. The lawsuit applies only to those who purchased ImmunityBio stock during the “class period”—likely between January 19, 2026 (when the misleading podcast statement was made) and March 13, 2026 (when the FDA warning was disclosed). Shareholders who bought before January 19 or after March 13 would fall outside this window, though the litigation team may expand the class period if additional evidence of earlier or later misconduct emerges.
Who Can Join the Class Action and What Recovery Looks Like
Any shareholder who purchased ImmunityBio stock during the alleged class period and suffered losses qualifies to join the litigation, assuming they can demonstrate causation between the misrepresentation and their losses. The law firms investigating the case—including Levi & Korsinsky and Hagens Berman—are actively seeking lead plaintiffs, individuals willing to serve as the named representatives of the entire investor class. Lead plaintiffs typically must have significant financial stake in the outcome and be available to work with counsel throughout the litigation. Recovery in securities class actions typically comes through settlement, which often generates a fund that’s distributed pro-rata based on each shareholder’s documented losses.
For example, if the settlement fund is $50 million and you held shares worth $500,000 at their peak, your recovery might be approximately 2 percent of your losses (a common recovery rate in biotech litigation). Some shareholders recover 5-10 percent of losses in more favorable settlements, while others recover substantially less if the litigation faces challenges or the company’s ability to pay is limited. The timeline for resolution typically spans 2-4 years from the initial filing of the class action complaint. Shareholders don’t need to hire their own lawyers or pay upfront fees—the class action is handled on a contingency basis, with counsel taking a percentage (usually 25-30 percent) of any recovery. The key requirement is that you can document your purchase and sale of shares during the class period, which is typically available through your brokerage statements.
The Broader Pattern of Biotech Misleading Claims
The ImmunityBio case isn’t an isolated incident but rather an example of a recurring pattern in the biotech sector. Small and mid-cap biotech companies operating in highly competitive oncology markets face intense pressure to tout their pipeline potential to attract investors and partners. The gap between preliminary data and final FDA approval creates opportunities for selective messaging and exaggeration. Company leaders often highlight promising early-stage results while downplaying limitations, safety signals, and regulatory hurdles that may emerge later.
The regulatory environment has tightened in recent years, with the FDA increasingly scrutinizing direct-to-consumer communications by biotech companies. The agency has issued numerous warning letters to companies making unsubstantiated cancer claims, suggesting that ImmunityBio’s behavior, while brazen, reflects a recurring challenge in how biotech companies market their assets. For investors, this reality underscores the importance of skepticism toward management claims that haven’t been validated by regulatory approval and peer-reviewed clinical data. A company chairman stating that an FDA-approved single-indication drug can treat “all cancers” should trigger immediate red flags, yet many investors rely on executive commentary rather than the actual regulatory documents.
Conclusion
The ImmunityBio Class Action Lawsuit represents a critical moment of accountability for a company that made sweeping claims about its cancer drug’s potential while the FDA’s actual approval was far more limited. Investors who relied on the chairman’s statements about ANKTIVA treating “all cancers” were misled about the drug’s commercial value and therapeutic scope. The $2 billion market capitalization loss and 21 percent stock decline reflect the market’s belated recognition of this gap between hype and regulatory reality.
If you purchased ImmunityBio shares during the class period between January 19, 2026, and March 13, 2026, you may be eligible to recover a portion of your losses by joining the class action. Contact Levi & Korsinsky, Hagens Berman, or other investigating firms to discuss your potential claim and receive a case evaluation. These lawsuits serve an essential function in holding company leadership accountable for misleading investors and ensuring that future biotech executives think carefully before making unsubstantiated claims about their pipeline.